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We report a case of a 23-year-old HIV-negative man 
with multidrug-resistant Mycobacterium tuberculosis that 
became evident while he was being treated for M. tuber-
culosis that was sensitive to all ﬁ  rst-line drugs. This case 
should alert clinicians to consider co-infection as a possible 
cause of recrudescent disease. 
A 
23-year-old HIV-negative man from Somalia immi-
grated to the United States 1.5 years before seeking 
treatment for his symptoms. The patient had a 3-week his-
tory of dry cough, dyspnea with exertion, pleuritic chest 
pain, fatigue, weight loss, and night sweats. A chest radio-
graph showed extensive left hemithorax opaciﬁ  cation, a 
left apical cavitary lesion, and right apical nodular lesions 
(Figure, panel A). Acid-fast bacillus (AFB) smears and cul-
ture were positive for Mycobacterium tuberculosis. Drug-
susceptibility testing demonstrated sensitivity to all ﬁ  rst-
line drugs. He received directly observed therapy (DOT), 
which consisted of isoniazid (300 mg/d), pyrazinamide 
(1,000 mg/d), rifampin (600 mg/d), and ethambutol (1,200 
mg/d). 
One month after starting treatment, he had persistent 
fatigue and shortness of breath and had gained no weight; 
follow-up chest radiograph showed no change. As a result, 
he received a prednisone dosage of 40 mg/d with a tapered 
dose to no prednisone over 2 months (1,2). Thereafter, he 
improved rapidly both symptomatically and radiographical-
ly. His cough abated, and he was unable to produce sputum. 
After 5 months of DOT, he again lost weight and felt 
fatigued. A repeat chest radiograph showed a new small 
cavitary lesion in the middle lobe of the right lung (Figure, 
panel B). At that time, repeat sputum sample was smear 
negative, but culture was positive for multidrug-resistant 
tuberculosis (MDR TB). Molecular characterization by 
spoligotyping and mycobacterial interspersed repeat units 
showed that the isolate from episode 1 differed genetically 
from that of episode 2 (Table) (3,4). Review of laboratory 
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Figure. Poster-anterior chest radiographs of patient with multidrug-
resistant tuberculosis. A) Radiograph taken at diagnosis, demon-
strating dense consolidation of the left lower lobe and lingula. A 
left apical cavity is present. Minimal change is also noted in the 
right mid-lung zone. B) Radiograph taken after 5 months of directly 
observed therapy. Marked clearance is noted on the left; however, 
a new small cavitary lesion with surrounding inﬁ  ltrate is noted in the 
right mid-lung zone (black arrow).Pansensitive and MDR M. tuberculosis Strains
records demonstrated that neither a switch in specimens 
nor cross-contamination were causes of this new ﬁ  nding. 
Repeat HIV testing was negative. Careful review of the pa-
tient’s contacts, exposures, and travel history did not show 
any obvious source of reinfection. The patient did not travel 
outside of the county before or after initial treatment. 
The patient received amikacin 15 mg/kg/d intrave-
nously, moxiﬂ  oxicin 400 mg/d, cycloserine 750 mg/d, and 
aminosalicylic acid 8 gm/d in accordance with drug-suscep-
tibility testing. Because of the extent of previous disease, 
surgical removal of the diseased lung was not performed. 
He was kept in isolation until 3 sputum smears were AFB 
negative. He gained weight, his energy increased, and ra-
diographic appearance of his lungs improved. At the time 
of his discharge, dosage of amikacin was decreased to 
3×/wk, and cycloserine was decreased to 250 mg/d based 
on the serum levels of each drug. The patient was instruct-
ed to receive treatment for a minimum of 24 months after 
the ﬁ  rst negative sputum culture. 
Molecular characterization showed that the 2 strains of 
M. tuberculosis were not related (3,4). Thus, the cause of 
treatment failure most likely was not due to development 
of resistance by the infecting strain. Among the >35,000 M. 
tuberculosis isolates characterized by the Centers for Dis-
ease Control and Prevention’s National Tuberculosis Geno-
typing Service (5), no exact genotype matches were found 
for the isolate from the ﬁ  rst episode and 3 exact genotype 
matches were found for the isolate from the second episode 
(P. Moonan, pers. comm.). All 3 matched genotypes came 
from persons originating from the same African region 
(Somalia and Ethiopia), which suggests a phylogeographic 
lineage adapted to a particular human population (6). How-
ever, none of the matches clustered in the same US region 
as the current case. Further investigation determined that 
interstate transmission in the United States was unlikely. A 
review of risk factors for reinfection, such as travel to areas 
endemic for TB or exposure to high-risk populations, was 
negative, suggesting that the second strain was acquired be-
fore treatment. On the basis of this information, we specu-
late that the patient acquired both strains before traveling to 
the United States.
We report an immunocompetent person with 2 strains 
of M. tuberculosis, one sensitive to all ﬁ  rst-line antituber-
culous drugs and one multidrug resistant. This case dem-
onstrates the ability of genotyping information to identify 
simultaneous infection with multiple strains of M. tuber-
culosis in a patient in whom treatment failure is suspected. 
In addition, this case exempliﬁ  es the critical importance of 
clinical monitoring during DOT in the prompt recognition 
and treatment of patients who have unsuspected simultane-
ous infections with multiple strains of M. tuberculosis. 
In patients who are not receiving DOT, a likely cause of 
treatment failure is nonadherence to the drug regimen (7). 
In patients who are receiving reliable DOT, deterioration 
may be explained by cryptic nonadherence, malabsorption, 
or laboratory error (7). In addition, exogenous reinfection 
should be considered as a possible reason for treatment fail-
ure or disease relapse (8–11). However, an underrecognized 
cause of treatment failure is mixed infection with >2 strains 
of M. tuberculosis (12–15). As reported previously (12), 
simultaneous infection with 2 competing strains should be 
considered when other common reasons are ruled out and 
a high index of suspicion is present. In the current case, the 
patient was receiving DOT and demonstrated clinical im-
provement while receiving an appropriate regimen based 
on drug-susceptibility testing. When his condition deterio-
rated clinically and sputum samples were culture positive, 
several possible causes of treatment failure were quickly 
discarded, including malabsorption, cryptic nonadherence, 
and laboratory error/contamination. 
As has been previously hypothesized, we conclude that 
this patient originally harbored both strains (12). The effect 
of disease at the patient’s initial presentation appears to 
have been predominantly due to the drug-sensitive strain, as 
evidenced by his initial clinical and radiographic improve-
ment and sputum conversion. The successful treatment of 
the drug-susceptible strain and the inherent resistance of 
the second strain to the ﬁ  rst-line medications enabled dis-
ease from the MDR TB strain to become apparent. 
The initial therapy in this case was complicated by de-
layed clinical response. The use of corticosteroids as an adju-
vant to antituberculosis medications in selected patients with 
severe disease has been documented to hasten resolution 
of symptoms and radiographic recovery without delaying 
clearance of organisms (1,2). Although the role of predni-
sone treatment in the emergence of the second strain is not 
clear, we believe the most important factor was the inherent 
antimicrobial resistance pattern of the second strain.
This case demonstrates the utility of DOT in assist-
ing with prompt recognition of a new infecting strain and 
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Table. Selected analyses of sputum from patient with tuberculosis over the course of treatment during 2007* 
Date Isolate Smear Culture Resistance† Spoligotype MIRU
Jan 4  1 Positive Positive None 000000004020771  224323-53313 
Jul 12  2 Negative Positive I, R, P, E  777756777760771  224325153226 
Sep 8  2 Positive Positive I, R, P, E  777756777760771  224325153226 
*Molecular characterization was performed on Sep 8 to confirm the presence of the second isolate and reassess for presence of the original isolate. 
MIRU, mycobacterial interspersed repeat units. 
†I, isoniazid; R, rifampin; P, pyrazinamide; E, ethambutol.  highlights the use of genotyping in the assessment of pos-
sible treatment failure. Heightened awareness of possible 
infection with multiple strains, either from reinfection or 
coinfection, is critical when monitoring patients who are 
not improving or who recrudesce despite therapy guided by 
drug-resistance testing. The use of genotyping is a neces-
sary tool in the evaluation of these patients. In particular, 
as in this case, a high index of suspicion for co-infection 
should be applied to persons originating from areas in 
which M. tuberculosis is hyperendemic. 
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